Introduction {#S0001}
============

Distraction osteogenesis (DO), also called callus distraction, callotasis, or osteodistraction, is a surgical process used to reconstruct skeletal deformities and lengthen the long bones of the body. A corticotomy is used to fracture the bone into two segments, and the two ends of the bone are gradually moved apart during the distraction phase, allowing new bone to form in the gap \[[@CIT0001], [@CIT0002]\]. Distraction osteogenesis has the benefit of simultaneously increasing bone length and the volume of surrounding soft tissues; thus this technique is widely used in the field of orthopedics and correction of craniofacial deformities \[[@CIT0003], [@CIT0004]\]. However, the overall treatment time of bone lengthening is still long and can be a cause of considerable morbidity for the patients.

Various approaches have been tested to promote bone formation during DO, such as mechanical compression, electrical and electromagnetic stimulation, low velocity ultrasound, and certain growth factors or cytokines \[[@CIT0005]--[@CIT0008]\]. Although some of these studies have yielded promising results, few of these approaches have been shown to be efficient in humans. Bone morphogenic proteins (BMPs) are among the most potent of the osteoinductive factors that play a crucial role in the process of embryological bone formation, fracture repair, and bone regeneration during DO \[[@CIT0009]--[@CIT0011]\]. Local injection of recombinant human (rh) BMP-2 has been shown to accelerate bone formation in a number of distraction models \[[@CIT0012]--[@CIT0014]\]. However, optimal bone formation appears to require a suitable carrier matrix because the BMP-2 administered in solution does not retain significant activity *in vivo* due to its short half-life.

Although numerous carriers have been shown to be compatible with the osteoinductive activity of rhBMPs \[[@CIT0015]--[@CIT0018]\], the use of natural biomaterials may be an attractive concept. Fibrin glue, a composite of fibrinogen and thrombin, is a physiologically relevant matrix. Its principal component, fibrin, is a natural wound healing matrix that allows cells to invade and interact in a wound and might provide a suitable matrix for bone healing \[[@CIT0019], [@CIT0020]\]. Previous studies have reported that fibrin glue is a potentially suitable biological vehicle for the transfer of cells and for the application of growth factors because of its biocompatibility, biodegradability and binding capacity to cells \[[@CIT0021]--[@CIT0023]\].

Here, we report a novel controlled-release system of rhBMP-2 using fibrin to accelerate bone formation in rabbit tibia lengthening. The *in vitro* release kinetics of rhBMP-2 was tested using the enzyme-linked immunosorbent assay (ELISA), and the *in vivo* effects of this delivery system were examined by radiology, histology, micro-computed tomography (micro-CT), and biomechanical testing.

Material and methods {#S0002}
====================

Preparation of fibrin glue {#S20003}
--------------------------

Fibrin glue was prepared using a Tissucols kit (Baxter AG, Vienna, Austria) according to the manufacturer\'s instructions, by ejecting equal volumes of a fibrinogen solution (25 µl) and two respective thrombin solutions (50 or 500 IU) through a two-channel syringe. Previous studies indicated that 100 µg of rhBMP-2 significantly increased callus formation. Thus, the dose of 100 µg of rhBMP-2 (R&D Systems, Minneapolis, USA) for each animal was used in this study. The rhBMP-2 was added to the thrombin component, mixed and then pipetted into a sterile syringe before addition of the fibrinogen component.

*In vitro* release test of rhBMP-2 {#S20004}
----------------------------------

Fibrin glue scaffolds with suspended rhBMP-2 (100 µg) were separately placed into microcentrifuge tubes with 1 ml of PBS and incubated at 37°C. After 24 h, the release medium was replaced with 1 ml of fresh PBS to maintain the continuous release of rhBMP-2 from the scaffold. The amount of rhBMP-2 released was quantified at room temperature using ELISA (BMP-2 Quantikine enzyme-linked immunosorbent assay kit, R&D Systems, Minneapolis, USA) according to the manufacturer\'s instructions. Such procedures were performed every 24 h in triplicate for over 21 days, and the mean value was used to graph the total cumulative release of rhBMP-2.

Animals and study design {#S20005}
------------------------

Forty-eight New Zealand white rabbits (6 months old, 2.5--3.2 kg) were included. The animal study was approved by the Animal Ethics Committee of Sichuan University in accordance with Guidelines for the Care and Use of Laboratory Animals. The animals were kept in separate cages with food and water under standardized environmental conditions with 12-h light/dark cycles, and allowed to move freely throughout the experimental period. Seven days after osteotomy surgery, the distraction procedure was started at a rate of 0.5 mm every 12 h (1.0 mm/day) for 10 days, and the actual lengthening of 10 mm was achieved. At the time of completion of distraction, all rabbits were randomly divided into 4 groups with 12 animals in each group according to the agents injected at the center of the lengthened gap: (a) control group with vehicle; (b) fibrin group with 50 µl of fibrin glue; (c) rhBMP-2 group with 100 µg of rhBMP-2; (d): rhBMP-2 + fibrin group with 100 µg of rhBMP-2 suspended in fibrin. All rabbits were sacrificed by injection of sodium pentobarbitone 8 weeks after drug treatment.

Surgery procedure {#S20006}
-----------------

All rabbits were anaesthetized by intravenous injection of sodium pentobarbital and sodium ketamine hydrochloride at doses of 20 mg/kg and 4 mg/kg body weight, respectively. Each animal was placed in the dorsal position, and a 2.0 cm incision was made along the medial side of the right hind leg to expose the tibia. The periosteum was then carefully elevated circumferentially. After a self-constructed external fixator was applied unilaterally to the tibia with four self-tapping screws, subperiosteal osteotomy was performed between the middle two screws using a fine wire saw at a level immediately below the area attached to the fibula ([Figure 1](#F0001){ref-type="fig"}). The periosteum, muscle, and skin were repositioned and closed with 3/0 silk sutures. The external fixator remained in place until necropsy.

![The picture taken during surgery and the radiograph immediately after the operation showed that the custom-made distractor was fixated on the rabbit tibia](AMS-12-27563-g001){#F0001}

Radiology {#S20007}
---------

Four and 8 weeks after drug treatment, radiographs of the distracted tibiae in standard antero-posterior position and lateral projections were taken using RADspeed at settings of 40 kilovolts and 1.2 milliamps. Quantitative analysis was performed using the pixel value ratio (PVR) in relation to original bone by a picture archiving communication system (PACS, INFINITT Co. Ltd, Seoul Korea) according to previous studies \[[@CIT0024], [@CIT0025]\].

Micro-CT examination {#S20008}
--------------------

Eight weeks after drug treatment, the regenerated bone tissue and the neighboring bone of the distracted tibia (6 specimens per group) were examined morphologically and quantitatively by a micro-CT 80 scanner (Scano Medical AG, Bassersdorf, Switzerland). Specimens were kept in 10% formalin to avoid drying during the scanning process. After three-dimensional (3D) reconstruction, the volume of interest (VOI) was defined as the 10 mm long distracted callus. The threshold was adjusted empirically to visualize the defect site and the mineralization and was then kept constant for every sample (375--1034 Hounsfield units for all reconstructions). Bone mineral density (BMD), bone mineral content (BMC), bone volume fraction (the ratio between bone volume and total volume, BV/TV) and cortical bone thickness (CBT) within the VOI of the regenerated bone were measured.

Histology {#S20009}
---------

After micro-CT examination, specimens (6 specimens per group) were fixed in 10% neutral formalin for 5 days and decalcified in 15% ethylene diamine tetraacetic acid (EDTA) for 6 weeks at 4°C. After dehydration, the specimens were embedded in paraffin and 6-µm coronal sections were stained with hematoxylin and eosin (H + E) for histological analysis.

Biomechanical testing {#S20010}
---------------------

For analysis of the biomechanical properties of the distracted tibiae, soft tissue was dissected carefully and a three-point bending test was performed immediately using a commercial materials testing system (Instron 4302; Instron, Norwood, MA, USA). The contralateral tibiae in the control group were also tested as a normal control. The load-displacement curve was recorded during the downward compression, and the ultimate load at failure (N; maximum force that the specimen sustained) was used for statistical analysis (6 specimens per group).

Statistical analysis {#S20011}
--------------------

All data are expressed as mean ± SD (standard deviation). One-way analysis of variance (ANOVA) and the Student-Newman-Keuls (SNK) test were conducted to compare differences between groups using SPSS 12.0 (SPSS, Chicago, IL, USA). Differences were considered to be significant when *p* \< 0.05.

Results {#S0012}
=======

*In vitro* release of rhBMP-2 {#S20013}
-----------------------------

Both thrombin 50 and 500 components were used to evaluate the release kinetics of rhBMP-2 from the fibrin glue. Similarities were observed in both groups and the released rhBMP-2 followed the same pattern ([Figure 2](#F0002){ref-type="fig"}). The cumulative level of rhBMP-2 released from the fibrin glue increased gradually over time. An initial burst release of over 70% rhBMP-2 was observed within the first 3 days, followed by sustained release detectable until day 17. Thus the thrombin 50 scaffolds were used for the *in vivo* experiment.

![*In vitro* analysis of release kinetics of rhBMP-2 from fibrin scaffolds revealed a sharp initial burst of over 70% total rhBMP-2 released in the first 3 days followed by a sustained release of up to 95% over 17 days. There was no significant difference between thrombin 50 and 500 groups](AMS-12-27563-g002){#F0002}

Radiological findings {#S20014}
---------------------

Radiological examination showed consecutive phases of new bone formation and remodeling in the distracted gap in all groups ([Figure 3](#F0003){ref-type="fig"}). For group comparison, there was no discernable difference of the radiodensity between the control and fibrin glue group. In the rhBMP-2 group, radiodensity of the distracted gap was higher compared to the control and fibrin glue group, suggesting increased mineralization. The highest radiodensity and best cortical bone bridging of the distracted gap were observed in the rhBMP-2 + fibrin group. Quantitative results of PVR in relation to original bone of the distracted tibiae using the PACS system are summarized in [Table I](#T0001){ref-type="table"}. Compared to rhBMP-2 alone, rhBMP-2 + fibrin significantly increased PVR values by 71.1% at 4 weeks and 37.5% at 8 weeks after drug treatment (*p* \< 0.05).

![Radiographic changes of the distracted gap between groups 4 and 8 weeks after drug treatment. Cortical continuity and bony union were achieved in all experimental groups 8 weeks after the completion of distraction, while bone regeneration within the distracted callus appeared to arise much earlier and faster in the fibrin + rhBMP-2 group compared to others](AMS-12-27563-g003){#F0003}

###### 

Quantitative results of pixel value ratio (PVR) in relation to original bone of the distracted tibiae using a picture archiving communication system

  Time \[weeks\]   Control      Fibrin       rhBMP-2                                        rhBMP-2/Fibrin
  ---------------- ------------ ------------ ---------------------------------------------- ----------------------------------------------
  4                0.25 ±0.04   0.23 ±0.05   0.38 ±0.07[\*](#TF0001){ref-type="table-fn"}   0.65 ±0.11[\#](#TF0002){ref-type="table-fn"}
  8                0.45 ±0.07   0.48 ±0.08   0.64 ±0.12[\*](#TF0001){ref-type="table-fn"}   0.88 ±0.13[\#](#TF0002){ref-type="table-fn"}

P-value \< 0.05 vs. control and fibrin group

p \< 0.05 vs. rhBMP-2 group (by one-way ANOVA and Student-Newman-Keuls test, n = 6 specimens in each group).

Micro-CT examination {#S20015}
--------------------

Micro-CT images are presented in [Figure 4](#F0004){ref-type="fig"} and the quantitative results in [Figure 5](#F0005){ref-type="fig"}. Consistent with radiological findings, the lowest values of BMC, BMD, BV/TV and CBT were observed in the control and fibrin groups. The rhBMP-2 group showed better results than those of the control and fibrin groups. Images from the rhBMP-2 + fibrin group revealed better cortical bone formation and bony bridging of the distracted gap than others, resulting in the best results of BMC, BMD, BV/TV and CBT between groups in quantitative analysis.

![The 3D micro-CT images 8 weeks after drug treatment revealed a superior quality of ossification of the distracted gap in the rabbits treated with rhBMP-2 + fibrin compared to others. Cross-sectional images at the center of the lengthened segment indicated that the rhBMP-2 + fibrin group showed the thickest cortical bone](AMS-12-27563-g004){#F0004}

![Results of quantitative micro-CT analysis of the distracted callus 8 weeks after drug treatment\
Data are expressed as mean ± SD. \*p \< 0.05 vs. control and fibrin group, and \#p \< 0.05 vs. rhBMP-2 group (by one-way ANOVA and Student-Newman-Keuls test, n = 6 specimens in each group). BMC -- bone mineral content, BMD -- bone mineral density, BV/TV (%) -- bone volume fraction, CBT -- cortical bone thickness.](AMS-12-27563-g005){#F0005}

Histology {#S20016}
---------

Histological images of the distracted tibiae are presented in [Figure 6](#F0006){ref-type="fig"}. Consistent with the radiological and micro-CT findings, the fibrin group produced no significant effect on callus formation compared to controls. Both rhBMP-2 treated groups exhibited thicker cortical bone than control and fibrin groups, but the rhBMP-2 + fibrin group showed the best results of cortical bone formation and bony bridging of the distracted gap.

![Longitudinal sections of the distracted tibiae prepared at 8 weeks after drug treatment (H + E staining, 40×)](AMS-12-27563-g006){#F0006}

Biomechanical testing {#S20017}
---------------------

The results of the three-point bending test are shown in [Figure 7](#F0007){ref-type="fig"}. There was no significant difference of the ultimate force of the lengthened tibiae between control and fibrin groups. Although the ultimate force of lengthened tibiae was significantly higher in both rhBMP-2 treated groups compared to controls, the rhBMP-2 + fibrin group induced the highest increase in the ultimate force, indicating the efficiency of rhBMP-2 + fibrin in enhancing bone formation at the distracted gap. However, the healing strength of distracted tibiae from the rhBMP-2 + fibrin group was still far from that of the contralateral normal tibiae in the control group.

![Ultimate force of the lengthened segments and the contralateral tibiae in the control group 8 weeks after drug treatment were measured by three-point bending test\
Data are expressed as mean ± SD; \*p \< 0.05 vs. control and fibrin group, ^\#^p \< 0.05 vs. rhBMP-2 group, and ^\$^p \< 0.05 vs. rhBMP-2 + fibrin group (by one-way ANOVA and Student-Newman-Keuls test, n = 6 specimens in each group).](AMS-12-27563-g007){#F0007}

Discussion {#S0018}
==========

BMP-2 acts primarily as a differentiation factor for bone and cartilage precursor cells, and has been shown to induce bone formation and healing of bony defects in a variety of animal experiments. The effect of local application of BMP-2 on bone formation during DO has been examined in different models. In all these studies, BMP-2 significantly increased bone formation within the lengthening segment, attributable mostly to the potent osteogenic ability of this mitogen. However, optimal bone formation is not achieved due to the short half-life of the BMP-2 administered in solution. Although previous studies reported that a higher dose or continuous injection of growth factor was more effective in accelerating bone formation \[[@CIT0026]--[@CIT0028]\], there are concerns over the risk of infection, long-term safety and associated costs. Incorporation of BMP-2 into suitable carriers can readily solve these problems because the physical binding of BMP-2 to the carrier material delays their rapid diffusion and the degradation by tissue proteinase, thereby considerably increasing its osteoinductive effect.

Several delivery systems have been developed for the sustained release of BMP-2 in bone defect and fracture healing, but only a few experiments have investigated the effects of BMP-2 in combination with carriers on bone healing in DO. Li *et al*. found that rhBMP-2 had positive effects on bone formation in lengthening the tibia when applied with absorbable collagen sponge (ACS) \[[@CIT0014]\]. However, no difference was found between the rhBMP-2/buffer and rhBMP-2/ACS groups, suggesting that ACS may not enable sustaining a steady rhBMP-2 level in the lengthened segment. Another important problem is that it requires a second surgical procedure for implantation of collagen sponge. In another study it was found that intermittent rhBMP-2-containing chitosan hydrogel infusion by a drug-release distractor improved radiologic and histological parameters of DO when compared with a single-dose BMP-2-chitosan-injected group \[[@CIT0028]\]. Conclusions about their results, however, are also difficult to make because of the lack of a control group treated with rhBMP-2 alone.

Fibrin glue is an excellent tissue sealant in clinical application and has received increasing interest as a reservoir to deliver growth factors in tissue engineering \[[@CIT0019]--[@CIT0022]\]. In this study *in vitro* release testing revealed sustained release of rhBMP-2 from the fibrin glue at both concentrations of thrombin. The fibrin glue eventually used in animals was composed of a low concentration of thrombin (thrombin 50), as it was difficult to incorporate the rhBMP-2 into the polymerizing glue using higher concentrations (thrombin 500). In a previous study fibrin composites laden with 25 µg IGF-I were observed to release effective concentrations of ligand for as long as 22 days *in vitro* \[[@CIT0029]\]. Another study suggested that grafted fibrin may last at least 2 weeks *in situ* \[[@CIT0030]\]. Similarly, in this study it was found that rhBMP-2 was released rapidly in the first 3 days from the fibrin glue with 70% of the total rhBMP-2, followed by sustained release up to 95% until day 17. When applied *in vivo*, this sharp burst may provide an initial stimulus for osteogenic cells and thus an accelerated onset of bone formation.

Previous studies showed that in the cellular environment fibrin specifically binds to a variety of proteins, including fibronectin, albumin, FGF2, and VEGF, and favors migration and proliferation of undifferentiated mesenchymal cells \[[@CIT0031]--[@CIT0033]\]. A previous study found that fibrin glue alone was effective as a scaffold to stimulate bone regeneration in a critical size rat cranial defect \[[@CIT0019]\]. However, the biological mechanism regulating bone regeneration in bone tissue engineering is different from that in DO. In this study no additional benefit for bone formation was observed in the group of fibrin glue alone compared with the empty control, suggesting that the possible role of fibrin glue in DO may be a growth factor carrier to achieve long-term persistence and thus maintain bioactive effects of rhBMP-2, but has no intrinsic effect on acceleration of bone formation by itself.

The consolidation phase is a key period for bone formation during DO, and delivery of exogenous BMP-2 at this stage will target osteogenic cells within the callus and may enhance its mineralization. In agreement with other findings \[[@CIT0014], [@CIT0026], [@CIT0028]\], our results clearly demonstrated accelerated bone ossification within the lengthened segment when rhBMP-2 was present. Further comparison between two rhBMP-2-treated groups showed that 8 weeks after the drug treatment, rabbits in the rhBMP-2/fibrin group showed a superior quality of ossification in radiological and histological appearance as well as higher values in micro-CT and mechanical testing when compared with the group of rhBMP-2 alone, indicating that incorporation of rhBMP-2 into fibrin contributed to and enhanced the therapeutic effects of rhBMP-2. Previous studies have shown that the effect of single use of rhBMP-2 on bone healing in DO is dose-dependent \[[@CIT0026], [@CIT0028]\]. Although the amount of rhBMP-2 injected in both rhBMP-2 treated groups was equal, rhBMP-2 without a carrier tends to diffuse easily and degrade by proteinase, and the effective concentration and exact dose of rhBMP-2 at the injection site may decrease rapidly to below the therapeutic level. The presence of fibrin glue, however, could protect rhBMP-2 from enzymatic degradation *in vivo* and keep it at a higher level by the sustained release of rhBMP-2 as a reservoir.

In conclusion, the results of this study indicated that treatment with rhBMP-2 suspended in fibrin accelerated bone regeneration within the distracted gap of rabbit tibia after an 8-week observation period, resulting in a stronger effect on callus formation and bony bridging of the distracted gap than rhBMP-2 alone. It suggests that fibrin is a potential carrier of rhBMP-2 to enhance its life-time and anabolic effect on bone formation.
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